We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Signal Disruption Causes Some Ovarian Cancers

By Biotechdaily staff writers
Posted on 21 Apr 2005
A recent study has revealed that ovarian cancer in women bearing a mutated form of the BRCA1 gene is caused by disruption of biochemical signaling that also disrupts granulosa cell regulation of epithelial cell growth.

BRCA1, known as the breast cancer gene, not only gives carriers of its mutated form an 80% chance of developing breast cancer, it also confers a 40% percent risk of developing ovarian cancer by the age of 70.

Investigators at the University of Southern California (USA) developed a line of mice lacking the BRCA1gene only in their ovarian granulosa cells. More...
These mice were found to be prone to development of ovarian tumors. However, the tumors did not arise in granulosa tissue. Rather, the tumors originated in epithelial tissue, and they carried normal BRCA1 genes. These findings were published in the March 29, 2005, issue of Current Biology.

"Before, we thought this gene was a classical tumor suppressor,” said senior author Dr. Louis Dubeau, professor of pathology at the University of Southern California. "If that were the case, it would mean that mutation of the gene would allow the cell it is in to grow out of control and create a tumor. Instead, what we have shown is that the gene actually acts indirectly, that it disrupts interactions between different cell types. The consequence of this finding is that ovarian cancer is the result of some biochemical problem that may be correctable or preventable. That is what makes this finding so exciting.”



Related Links:
University of Southern California

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.